Member of the Association of American Physicians
Oliver W. Press spends much of his time researching Internal medicine, Surgery, Lymphoma, Radioimmunotherapy and Monoclonal antibody. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Oncology and Tositumomab. His studies deal with areas such as Total body irradiation and Cyclophosphamide as well as Gastroenterology.
His Lymphoma research incorporates themes from Ibritumomab tiuxetan and Clinical trial. His Radioimmunotherapy study incorporates themes from Nuclear medicine and Biodistribution. The various areas that Oliver W. Press examines in his Monoclonal antibody study include Cancer cell, Molecular biology, B cell and Antigen.
The scientist’s investigation covers issues in Internal medicine, Radioimmunotherapy, Oncology, Lymphoma and Surgery. As part of his studies on Internal medicine, Oliver W. Press frequently links adjacent subjects like Gastroenterology. The concepts of his Radioimmunotherapy study are interwoven with issues in Cancer research, Nuclear medicine and Biodistribution.
His study in Oncology is interdisciplinary in nature, drawing from both Chemotherapy regimen, Tositumomab, CHOP, Regimen and Mantle cell lymphoma. His Lymphoma research integrates issues from Clinical trial and Radiation therapy. His studies in Transplantation integrate themes in fields like B-cell lymphoma, Total body irradiation, Leukemia and Bone marrow.
His primary scientific interests are in Internal medicine, Oncology, Radioimmunotherapy, Lymphoma and Transplantation. The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. Oliver W. Press interconnects Regimen, Mantle cell lymphoma, Diffuse large B-cell lymphoma, B-cell lymphoma and Autologous transplantation in the investigation of issues within Oncology.
His Radioimmunotherapy research is multidisciplinary, incorporating perspectives in Cancer research and Toxicity. His Lymphoma research includes themes of Cancer and Clinical trial. His Transplantation research includes elements of Haematopoiesis and Multiple myeloma.
Oliver W. Press focuses on Internal medicine, Lymphoma, Oncology, Cancer research and Gastroenterology. His work in Internal medicine tackles topics such as Surgery which are related to areas like Hazard ratio. The concepts of his Lymphoma study are interwoven with issues in Cancer, Radiation therapy and BCL6.
The Oncology study combines topics in areas such as Gene rearrangement, Clinical trial and Chronic lymphocytic leukemia. His Cancer research study combines topics from a wide range of disciplines, such as Immunology, Immunogenicity, B cell, Pretargeted Radioimmunotherapy and CD20. His research is interdisciplinary, bridging the disciplines of Chemotherapy and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
Daming Shan;Jeffrey A. Ledbetter;Oliver W. Press.
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
Oliver W. Press;Janet F. Eary;Frederick R. Appelbaum;Paul J. Martin.
The New England Journal of Medicine (1993)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G. Till;Brian G. Till;Michael C. Jensen;Jinjuan Wang;Eric Y. Chen.
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
M. S. Kaminski;A. D. Zelenetz;O. W. Press;M. Saleh.
Journal of Clinical Oncology (2001)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Brian G. Till;Brian G. Till;Michael C. Jensen;Michael C. Jensen;Jinjuan Wang;Xiaojun Qian.
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
OW Press;F Appelbaum;JA Ledbetter;PJ Martin.
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
O.W Press;O.W Press;F Appelbaum;F Appelbaum;P.J Martin;P.J Martin;D.C Matthews;D.C Matthews.
The Lancet (1995)
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Daming Shan;Jeffrey A. Ledbetter;Oliver W. Press.
Cancer Immunology, Immunotherapy (2000)
Hickman Catheter Infections in Patients With Malignancies
Oliver W. Press;Paul G. Ramsey;Eric B. Larson;Alexander Fefer.
New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Richard I. Fisher;Michael LeBlanc;Oliver W. Press;David G. Maloney.
Journal of Clinical Oncology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: